Literature DB >> 22725698

The use of therapeutic peptides to target and to kill cancer cells.

R J Boohaker1, M W Lee, P Vishnubhotla, J M Perez, A R Khaled.   

Abstract

Peptide therapeutics is a promising field for emerging anti-cancer agents. Benefits include the ease and rapid synthesis of peptides and capacity for modifications. An existing and vast knowledge base of protein structure and function can be exploited for novel peptide design. Current research focuses on developing peptides that can (1) serve as tumor targeting moieties and (2) permeabilize membranes with cytotoxic consequences. A survey of recent findings reveals significant trends. Amphiphilic peptides with clusters of hydrophobic and cationic residues are features of anti-microbial peptides that confer the ability to eradicate microbes and show considerable anti-cancer toxicity. Peptides that assemble and form pores can disrupt cell or organelle membranes and cause apoptotic or necrotic death. Cell permeable and tumor-homing peptides can carry biologically active cargo to tumors or tumor vasculature. The challenge lies in developing the clinical application of therapeutic peptides. Improving delivery to tumors, minimizing non-specific toxic effects and discerning pharmacokinetic properties are high among the needs to produce a powerful therapeutic peptide for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22725698      PMCID: PMC4537071          DOI: 10.2174/092986712801661004

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  128 in total

1.  Effect of defensin peptides on eukaryotic cells: primary epithelial cells, fibroblasts and squamous cell carcinoma cell lines.

Authors:  Michiko Nishimura; Yoshihiro Abiko; Yoshihito Kurashige; Maiko Takeshima; Mami Yamazaki; Kaoru Kusano; Masato Saitoh; Keisuke Nakashima; Takashi Inoue; Tohru Kaku
Journal:  J Dermatol Sci       Date:  2004-11       Impact factor: 4.563

2.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

Review 3.  BCL-2 family antagonists for cancer therapy.

Authors:  Guillaume Lessene; Peter E Czabotar; Peter M Colman
Journal:  Nat Rev Drug Discov       Date:  2008-12       Impact factor: 84.694

4.  Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery.

Authors:  Mark R Gilbert; John Kuhn; Kathleen R Lamborn; Frank Lieberman; Patrick Y Wen; Minesh Mehta; Timothy Cloughesy; Andrew B Lassman; Lisa M Deangelis; Susan Chang; Michael Prados
Journal:  J Neurooncol       Date:  2011-07-08       Impact factor: 4.130

5.  Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria.

Authors:  K Matsuzaki; K Sugishita; M Harada; N Fujii; K Miyajima
Journal:  Biochim Biophys Acta       Date:  1997-07-05

6.  A novel pH-responsive polysaccharidic ionic complex for proapoptotic D-(KLAKLAK)2 peptide delivery.

Authors:  Bo Reum Lee; Kyung Taek Oh; Young Taik Oh; Hye Jung Baik; So Young Park; Yu Seok Youn; Eun Seong Lee
Journal:  Chem Commun (Camb)       Date:  2011-02-14       Impact factor: 6.222

Review 7.  Still embedded together binding to membranes regulates Bcl-2 protein interactions.

Authors:  B Leber; J Lin; D W Andrews
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

8.  Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.

Authors:  A Santoro; T Pressiani; G Citterio; G Rossoni; G Donadoni; F Pozzi; L Rimassa; N Personeni; S Bozzarelli; G Rossoni; S Colombi; F G De Braud; F Caligaris-Cappio; A Lambiase; C Bordignon
Journal:  Br J Cancer       Date:  2010-08-17       Impact factor: 7.640

9.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

10.  In search of a novel target - phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy.

Authors:  Sabrina Riedl; Beate Rinner; Martin Asslaber; Helmut Schaider; Sonja Walzer; Alexandra Novak; Karl Lohner; Dagmar Zweytick
Journal:  Biochim Biophys Acta       Date:  2011-07-26
View more
  79 in total

1.  Rational development of a cytotoxic peptide to trigger cell death.

Authors:  Rebecca J Boohaker; Ge Zhang; Michael W Lee; Kathleen N Nemec; Santimukul Santra; J Manuel Perez; Annette R Khaled
Journal:  Mol Pharm       Date:  2012-05-29       Impact factor: 4.939

2.  ACPred-FL: a sequence-based predictor using effective feature representation to improve the prediction of anti-cancer peptides.

Authors:  Leyi Wei; Chen Zhou; Huangrong Chen; Jiangning Song; Ran Su
Journal:  Bioinformatics       Date:  2018-12-01       Impact factor: 6.937

3.  Anti-metastatic Effects of Cationic KT2 Peptide (a Lysine/Tryptophan-rich Peptide) on Human Melanoma A375.S2 Cells.

Authors:  Jing-Gung Chung; Jureerut Daduang; Pornsuda Maraming; Sompong Klaynongsruang; Patcharee Boonsiri; Shu-Fen Peng; Sakda Daduang; Prapenpuksiri Rungsa; Ratree Tavichakorntrakool
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

4.  Modulating Protein Stability to Switch Toxic Protein Function On and Off in Living Cells.

Authors:  Frederik Faden; Stefan Mielke; Nico Dissmeyer
Journal:  Plant Physiol       Date:  2019-01-24       Impact factor: 8.340

5.  Peptide-Membrane Interactions by Spin-Labeling EPR.

Authors:  Tatyana I Smirnova; Alex I Smirnov
Journal:  Methods Enzymol       Date:  2015-09-26       Impact factor: 1.600

6.  Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide.

Authors:  Rania Bassiouni; Kathleen N Nemec; Ashley Iketani; Orielyz Flores; Anne Showalter; Amr S Khaled; Priya Vishnubhotla; Robert W Sprung; Charalambos Kaittanis; Jesus M Perez; Annette R Khaled
Journal:  Clin Cancer Res       Date:  2016-03-24       Impact factor: 12.531

7.  Targeted drug delivery using iRGD peptide for solid cancer treatment.

Authors:  Xiangsheng Liu; Jinhong Jiang; Ying Ji; Jianqin Lu; Ryan Chan; Huan Meng
Journal:  Mol Syst Des Eng       Date:  2017-08-16

Review 8.  Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative review.

Authors:  Arrigo F G Cicero; Federica Fogacci; Alessandro Colletti
Journal:  Br J Pharmacol       Date:  2016-09-29       Impact factor: 8.739

Review 9.  DNA nanomaterials for preclinical imaging and drug delivery.

Authors:  Dawei Jiang; Christopher G England; Weibo Cai
Journal:  J Control Release       Date:  2016-08-13       Impact factor: 9.776

10.  Anticancer activity of Helicobacter pylori ribosomal protein (HPRP) with iRGD in treatment of colon cancer.

Authors:  Atieh Yaghoubi; Fereshteh Asgharzadeh; Aref Movaqar; Kiarash Ghazvini; Seyed Mahdi Hassanian; Amir Avan; Majid Khazaei; Saman Soleimanpour
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-12       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.